BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 14606351)

  • 1. [Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor].
    Gelderblom H; Hogendoorn PC; van der Graaf WT; Verweij J
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2051-5. PubMed ID: 14606351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal stromal tumours.
    Connolly EM; Gaffney E; Reynolds JV
    Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New oncological treatment principle with imatinib].
    Kuenen BC; Pinedo HM
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gastrointestinal stromal tumor].
    Nishida T; Ohmori T; Matsuda H
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):331-6. PubMed ID: 15045935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
    Chen LL; Trent JC; Wu EF; Fuller GN; Ramdas L; Zhang W; Raymond AK; Prieto VG; Oyedeji CO; Hunt KK; Pollock RE; Feig BW; Hayes KJ; Choi H; Macapinlac HA; Hittelman W; Velasco MA; Patel S; Burgess MA; Benjamin RS; Frazier ML
    Cancer Res; 2004 Sep; 64(17):5913-9. PubMed ID: 15342366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal stromal tumors (GISTs): a pathology view point.
    Sornmayura P
    J Med Assoc Thai; 2009 Jan; 92(1):124-35. PubMed ID: 19260254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tyrosine kinase inhibitor as a targeted therapy for GIST tumors].
    Joensuu H
    Duodecim; 2002; 118(22):2305-12. PubMed ID: 12523107
    [No Abstract]   [Full Text] [Related]  

  • 9. [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)].
    Des Guetz G; De Mestier P; Pierga JY
    J Chir (Paris); 2002 Oct; 139(5):268-73. PubMed ID: 12410126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
    Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias.
    Blay P; Astudillo A; Buesa JM; Campo E; Abad M; García-García J; Miquel R; Marco V; Sierra M; Losa R; Lacave A; Braña A; Balbín M; Freije JM
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4089-95. PubMed ID: 15217944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
    Ali S; Ali S
    Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
    de Jong FA; Verweij J
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
    Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
    Renouf DJ; Wilson L; Blanke CD
    Clin Cancer Res; 2009 Jun; 15(12):3908-11. PubMed ID: 19509180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
    Shiba K; Matsumoto T; Hirota S
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal stromal tumors and the evolution of targeted therapy.
    Sanborn RE; Blanke CD
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review.
    Sawaki A; Yamao K
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S44-9. PubMed ID: 15309514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal stromal tumour--a paradigm shift in management of solid tumours.
    Bapsy PP; Prabhash K; Babu KG; Girish MH
    J Assoc Physicians India; 2003 Aug; 51():801-4. PubMed ID: 14651144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gastrointestinal stromal tumors (GIST)].
    Reichardt P; Pink D; Mrozek A; Lindner T; Hohenberger P
    Z Gastroenterol; 2004 Apr; 42(4):327-31. PubMed ID: 15095124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.